Drug Trial Radar · NCT04456387
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Oct 15, 2020
Primary completion
Sep 30, 2021
Study completion Sep 30, 2021
Sponsor
- Lead sponsor
- Zhengzhou Gensciences IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the Prevention and Treatment of Bleeding in patients with hemophilia A. The secondary objectives are to evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the prevention and treatment of bleeding episodes, to investigate the quality of life in patients who used the FRSW107.
Conditions
- Hemophilia A
Interventions
Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug
Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionDrug
Participants received prophylaxis treatment at 50 IU/kg every three days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - score of bleeding symptoms and Vital signs.Time frame: For the duration of study participation, 6 months.
- Part B- Annualized Bleeding Rates(ABR).Time frame: For the duration of study participation, 6 months.
- Part B-Number of target joints.Time frame: For the duration of study participation, 6 months.
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Capital Medical University affiliated Beijing Children's Hospital
Beijing, Beijing Municipality, China
Chongqing Three Gorges Central Hospital
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangzhou, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Henan provincial People's Hospital
Zhengzhou, He'nan, China
Henan Cancer Hospital
Zhengzhou, He'nan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Jinan central hospital
Ji'nan, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.